At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
IV busulfan +2 moredrug
Likely dose
bortezomib 1.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Nov 9, 2009·Updated May 13, 2026
In Brief
A Phase 2 clinical trial evaluating IV busulfan, bortezomib, and 1 other intervention for Multiple Myeloma. Completed, enrolled 30 participants across 13 sites in 2 countries.
Detailed Summary
Study for the outcome and safety of individualized busulfan dosing with bortezomib for patients preparing for a second stem cell transplant to treat multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2009
Enrollment StartMay 2010
Primary CompletionMar 2012
TodayJul 2026
First PostedNov 9, 2009
Enrollment StartMay 1, 2010
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.6 years ago
Interventions
IV busulfandrug
PK-directed dosing of IV busulfan for 4 days
bortezomibdrug
Single IV bortezomib at a dose of 1.3 mg/m\^2.
Autologous Hematopoietic Stem Cell Transplant (HSCT)procedure